June 6, 2014UChicago Leaves Its Imprint on the 50th Annual ASCO Meeting
The theme for ASCO’s 50th annual conference, Science and Society, reflects the growing need to assess maximizing benefits to patients while providing value in a rapidly changing health care environment.
May 29, 2014Tiny Mutation Triggers Drug Resistance for Patients with One Type of Leukemia
A multi-institutional team of researchers has pinpointed exactly what goes wrong when chronic lymphocytic leukemia (CLL) patients develop resistance to the highly effective drug ibrutinib.
May 8, 20142014 AACR Annual Meeting Highlights
The theme for this year’s 105th AACR meeting was “Harnessing Breakthroughs – Targeting Cures.” UCCCC faculty and investigators led a number of exciting session and delivered top-notch papers and posters.
April 8, 2014The Power of Mobilizing the Immune System for Cancer Therapy
Heralded as the “Breakthrough of 2013” by the leading scientific journal Science, cancer immunotherapy is finally getting the attention many in the field thought it long deserved.
March 4, 2014New Treatment Protocol for Rectal Cancer Saves Pregnant Woman and Her Baby
A few weeks after she learned she was pregnant with her first child, Michelle Jahnke was diagnosed with stage 3 rectal cancer. A novel approach by her UCM team saved her and her baby.
Recent Posts by UChicago Cancer Experts
Vander Griend’s lab examines the role of stem cells, Sox2, and the Hox gene family in prostate cancer development and potential treatment.
The optimism for recovery surrounding J.P. Morgan CEO Jamie Dimon’s public diagnosis of throat cancer highlights the advances made in treating head and neck cancers.
Cancer care has a new side effect: financial toxicity. Along with the distress of diagnosis and treatment, more patients are suffering anxiety from the anticipated large, unpredictable costs of treatment and loss of ability to work.
Recent national statistics show death rates for cancer are on the decline. Research has played a big part in this positive trend. But federal budget cuts threaten the progress made over the past several decades. Now is not the time to let up.
Physicians and scientists from the University of Chicago will play major roles at ASCO’s annual meeting. High-profile topics include studies of new immunotherapy protocols and novel targeted therapies. But much of the chatter will be on who’s picking up the tab?